Dear shareholders and valuable followers,

It is with great joy and enthusiasm that I take on the role as CEO of Attana. As mentioned in the first press release, the board aims to bring about a change, increasing sales by reprioritizing the time for the team to focus more on the commercial agenda, and work more structed with customer relations and product development. This is a good starting point and in line with my short-term strategy.

Another short-term goal for Attana is to become cash flow positive. To balance revenues and costs is the foundation of all sustainable businesses, and we need to take decisions in line with that strategy. Concurrently, we are restructuring our customer relationships and defining clearer roles and responsibilities internally while reviewing our cost level. Commercially, we are focusing on five revenue streams: CRO, instrument sales, service, consumables, and immunity profiles. The first four are related to our traditional Life Science business and will be the backbone of our business in the coming year. The fifth revenue stream, the immunity profiles, is connected to Diagnostics and defined as our growth market.

Shortly, I will participate in a podcast where I will share my views and ideas on how to stabilize and grow our business. We will share the event in our social media channels in mid-October.  

Our technology and the IP we hold is world-leading but also underestimated by markets and certain conservative competitors and customers. I can understand that, but I can’t accept it. We shall work hard to convince the market differently. As a team, we shall be present and assist our customers in their highly important projects, exceed their expectations and solve their scientific problems continuously. More than 150 publications and the outcome from our customers' clinical trials sends a clear message, the drug development process can be improved and yet more cost efficient with our technology. Additionally, increased cost savings for hospitals through more precise diagnostics, and an improved understanding among citizens regarding their own vaccine protection is very beneficial for the society but not yet addressed.

Thank you for being an important part of our global community.

Best regards,

Marcus Söderberg
CEO, Attana

For more information, please contact:

Teodor Aastrup, CSO
teodor.aastrup@attana.com
+46 708862300

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.

About Attana

Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com

Tags: